Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate
Vivos Therapeutics, Inc. +0.41%
Vivos Therapeutics, Inc. VVOS | 2.47 | +0.41% |
Vivos Therapeutics (NASDAQ:
VVOS) reported quarterly losses of $(3.05) per share which missed the analyst consensus estimate of $(1.91) by 59.69 percent. The company reported quarterly sales of $3.248 million which missed the analyst consensus estimate of $3.406 million by 4.64 percent. This is a 17.77 percent decrease over sales of $3.950 million the same period last year.